Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: CCS648 who wrote (867)	2/10/2025 2:57:16 PM
From: End2War	2 Recommendations Recommended By bobbseytwins2001 rodneyh07 Respond to of 1230

PSS seems convinced he understands Anktiva's MOA. I like this ending: " We have initiated this trial where before you get the radiotherapy, we will give Anktiva to rescue the lymphocytes. We will also give an adeno PSA that generates memory T cells [for] prostate cancer. If you want to add radiation to that, you do the radiation. We can avoid ADT and monitor the patient's PSA. What I will be showing at the AUA is that we've initiated that now as a full trial. *[There] is very exciting data, which we will share."*